Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series

Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. Systematic review of real-life mortality in t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Senta Frol, Dimitrios Sagris, Mišo Šabovič, George Ntaios, Janja Pretnar Oblak
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	dabigatran idarucizumab reversal agent intracranial hemorrhage in-hospital mortality Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/fee5726ca7584226ac90e79af65ec1fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fee5726ca7584226ac90e79af65ec1fa
record_format	dspace
spelling	oai:doaj.org-article:fee5726ca7584226ac90e79af65ec1fa2021-11-30T15:49:23ZDabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series1664-229510.3389/fneur.2021.727403https://doaj.org/article/fee5726ca7584226ac90e79af65ec1fa2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fneur.2021.727403/fullhttps://doaj.org/toc/1664-2295Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. Systematic review of real-life mortality in these patients is missing.Objectives: A review of all published dabigatran-related ICH cases treated with idarucizumab was performed. We aimed to estimate in-hospital mortality rate in these patients.Method: We searched PubMed and Scopus for all published cases of ICH in idarucizumab/dabigatran-treated patients until May 15, 2021. The assessed outcome was in-hospital mortality.Results: We identified six eligible studies (case series) with 386 patients and 54 single case reports. In-hospital mortality rate was 11.4% in the case series and 9.7% in the case reports.Conclusions: Our analysis provides clinically relevant quantitative data regarding in-hospital mortality in idarucizumab/dabigatran-treated patients with ICH, which is estimated to be 9.7–11.4%.Senta FrolDimitrios SagrisMišo ŠabovičGeorge NtaiosJanja Pretnar OblakFrontiers Media S.A.articledabigatranidarucizumabreversal agentintracranial hemorrhagein-hospital mortalityNeurology. Diseases of the nervous systemRC346-429ENFrontiers in Neurology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dabigatran idarucizumab reversal agent intracranial hemorrhage in-hospital mortality Neurology. Diseases of the nervous system RC346-429
spellingShingle	dabigatran idarucizumab reversal agent intracranial hemorrhage in-hospital mortality Neurology. Diseases of the nervous system RC346-429 Senta Frol Dimitrios Sagris Mišo Šabovič George Ntaios Janja Pretnar Oblak Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
description	Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. Systematic review of real-life mortality in these patients is missing.Objectives: A review of all published dabigatran-related ICH cases treated with idarucizumab was performed. We aimed to estimate in-hospital mortality rate in these patients.Method: We searched PubMed and Scopus for all published cases of ICH in idarucizumab/dabigatran-treated patients until May 15, 2021. The assessed outcome was in-hospital mortality.Results: We identified six eligible studies (case series) with 386 patients and 54 single case reports. In-hospital mortality rate was 11.4% in the case series and 9.7% in the case reports.Conclusions: Our analysis provides clinically relevant quantitative data regarding in-hospital mortality in idarucizumab/dabigatran-treated patients with ICH, which is estimated to be 9.7–11.4%.
format	article
author	Senta Frol Dimitrios Sagris Mišo Šabovič George Ntaios Janja Pretnar Oblak
author_facet	Senta Frol Dimitrios Sagris Mišo Šabovič George Ntaios Janja Pretnar Oblak
author_sort	Senta Frol
title	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
title_short	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
title_full	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
title_fullStr	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
title_full_unstemmed	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
title_sort	dabigatran reversal with idarucizumab and in-hospital mortality in intracranial hemorrhage: a systematic review of real-life data from case reports and case series
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/fee5726ca7584226ac90e79af65ec1fa
work_keys_str_mv	AT sentafrol dabigatranreversalwithidarucizumabandinhospitalmortalityinintracranialhemorrhageasystematicreviewofreallifedatafromcasereportsandcaseseries AT dimitriossagris dabigatranreversalwithidarucizumabandinhospitalmortalityinintracranialhemorrhageasystematicreviewofreallifedatafromcasereportsandcaseseries AT misosabovic dabigatranreversalwithidarucizumabandinhospitalmortalityinintracranialhemorrhageasystematicreviewofreallifedatafromcasereportsandcaseseries AT georgentaios dabigatranreversalwithidarucizumabandinhospitalmortalityinintracranialhemorrhageasystematicreviewofreallifedatafromcasereportsandcaseseries AT janjapretnaroblak dabigatranreversalwithidarucizumabandinhospitalmortalityinintracranialhemorrhageasystematicreviewofreallifedatafromcasereportsandcaseseries
_version_	1718406542161608704

Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series

Ejemplares similares